Novavax, Inc. (LON:0A3S)

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of GBP 997.45 million. The enterprise value is 716.52 million.

Market Cap	997.45M
Enterprise Value	716.52M

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.42M
Shares Outstanding	n/a
Shares Change (YoY)	+30.54%
Shares Change (QoQ)	-0.23%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.72M

Valuation Ratios

The trailing PE ratio is 3.23.

PE Ratio	3.23
Forward PE	n/a
PS Ratio	1.27
PB Ratio	36.32
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.40, with an EV/FCF ratio of -1.54.

EV / Earnings	2.32
EV / Sales	0.91
EV / EBITDA	2.40
EV / EBIT	2.67
EV / FCF	-1.54

Financial Position

The company has a current ratio of 2.36, with a Debt / Equity ratio of 6.07.

Current Ratio	2.36
Quick Ratio	2.16
Debt / Equity	6.07
Debt / EBITDA	0.56
Debt / FCF	-0.36
Interest Coverage	15.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	14.52%
Return on Invested Capital (ROIC)	467.59%
Return on Capital Employed (ROCE)	38.67%
Revenue Per Employee	827,055
Profits Per Employee	324,180
Employee Count	952
Asset Turnover	0.68
Inventory Turnover	47.58

Taxes

In the past 12 months, Novavax has paid 6.25 million in taxes.

Income Tax	6.25M
Effective Tax Rate	1.98%

Stock Price Statistics

The stock price has decreased by -40.92% in the last 52 weeks. The beta is 2.68, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.68
52-Week Price Change	-40.92%
50-Day Moving Average	7.71
200-Day Moving Average	7.63
Relative Strength Index (RSI)	59.58
Average Volume (20 Days)	149,267

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.78

Income Statement

In the last 12 months, Novavax had revenue of GBP 787.36 million and earned 308.62 million in profits. Earnings per share was 1.86.

Revenue	787.36M
Gross Profit	450.25M
Operating Income	267.43M
Pretax Income	314.87M
Net Income	308.62M
EBITDA	297.44M
EBIT	267.43M
Earnings Per Share (EPS)	1.86

Balance Sheet

The company has 446.92 million in cash and 166.77 million in debt, giving a net cash position of 280.15 million.

Cash & Cash Equivalents	446.92M
Total Debt	166.77M
Net Cash	280.15M
Net Cash Per Share	n/a
Equity (Book Value)	27.46M
Book Value Per Share	0.17
Working Capital	387.12M

Cash Flow

In the last 12 months, operating cash flow was -460.52 million and capital expenditures -3.48 million, giving a free cash flow of -464.01 million.

Operating Cash Flow	-460.52M
Capital Expenditures	-3.48M
Free Cash Flow	-464.01M
FCF Per Share	n/a

Margins

Gross margin is 57.18%, with operating and profit margins of 33.96% and 39.20%.

Gross Margin	57.18%
Operating Margin	33.96%
Pretax Margin	39.99%
Profit Margin	39.20%
EBITDA Margin	37.78%
EBIT Margin	33.96%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.54%
Shareholder Yield	n/a
Earnings Yield	30.94%
FCF Yield	-46.52%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Novavax has an Altman Z-Score of -1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.72
Piotroski F-Score	5